Prometheus Launches Monitoring Test for Inflammatory Bowel Disease Management

Prometheus Laboratories announced the launch of its monitoring test, PROMETHEUS Anser IFX, which measures infliximab (Remicade; Janssen Biotech) and infliximab antibody levels in one sample to be used among inflammatory bowel disease (IBD) patients, helping physicians identify potential causes for loss of treatment response and helping to guide patient management decisions.

The Crohn’s and Colitis Foundation of America estimates that approximately 1.4 million Americans suffer from IBD.  Approximately 50% of IBD patients using infliximab may eventually experience a loss of treatment response during their treatment.  For some patients, this loss of treatment response may be the result of insufficient infliximab levels.  For others, the loss may be due to the development of antibodies to infliximab (ATI).  If the loss of treatment response is due to the development of ATI, increasing the infliximab dose – the most common first step for physicians – may be less effective than switching to another treatment agent. PROMETHEUS Anser IFX test was verified with more than 3,000 IBD clinical patient samples.

For more information call (888) 423-5227 or visit www.prometheuslabs.com.